290 related articles for article (PubMed ID: 19438555)
1. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
[No Abstract] [Full Text] [Related]
2. Does adalimumab cause bullous pemphigoid?
Toosi S; Bystryn JC
Clin Exp Dermatol; 2010 Oct; 35(7):795. PubMed ID: 20831605
[No Abstract] [Full Text] [Related]
3. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy.
Saraceno R; Citarella L; Spallone G; Chimenti S
Clin Exp Dermatol; 2008 Mar; 33(2):154-5. PubMed ID: 18021271
[TBL] [Abstract][Full Text] [Related]
4. Urticarial vasculitis due do infliximab.
Goulão J; Cunha H; Anes I; Bártolo E; Furtado C; Serrano P; Brandão FM
J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):882-3. PubMed ID: 18462298
[No Abstract] [Full Text] [Related]
5. A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.
Wang G; Hu X; Han S; Zhou M
J Dermatolog Treat; 2024 Dec; 35(1):2366535. PubMed ID: 38945532
[No Abstract] [Full Text] [Related]
6. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
de Groot M; de Rie MA; Bos JD
Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
[No Abstract] [Full Text] [Related]
7. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient.
Onsun N; Sallahoglu K; Dizman D; Su Ö; Tosuner Z
Eur J Dermatol; 2017 Feb; 27(1):81-82. PubMed ID: 27777186
[No Abstract] [Full Text] [Related]
8. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
Teraki Y; Takahashi A; Inoue Y; Takamura S
Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
[No Abstract] [Full Text] [Related]
9. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
10. Efalizumab-induced bullous pemphigoid.
Duong TA; Buffard V; André C; Ortonne N; Revuz J; Bagot M; Roujeau JC
J Am Acad Dermatol; 2010 Jan; 62(1):161-162. PubMed ID: 20082902
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction?
Monnier-Murina K; Du Thanh A; Merlet-Albran S; Guillot B; Dereure O
Dermatology; 2009; 219(1):89-90. PubMed ID: 19270438
[No Abstract] [Full Text] [Related]
12. Eczematous eruption in patients with psoriasis during risankizumab treatment.
Kromer C; Schön MP; Mössner R
Eur J Dermatol; 2020 Oct; 30(5):599-601. PubMed ID: 33185530
[No Abstract] [Full Text] [Related]
13. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports.
Boussemart L; Jacobelli S; Batteux F; Goulvestre C; Grange P; Carlotti A; Morini JP; Gorin I; Ziza JM; Avril MF; Dupin N
Dermatology; 2010; 221(3):201-5. PubMed ID: 20720390
[TBL] [Abstract][Full Text] [Related]
14. Development of bullous pemphigoid during secukinumab treatment for psoriasis.
Ho PH; Tsai TF
J Dermatol; 2017 Sep; 44(9):e220-e221. PubMed ID: 28543960
[No Abstract] [Full Text] [Related]
15. Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab.
Becker JG; Mundi JP; Newlove T; Mones J; Shupack J
J Am Acad Dermatol; 2012 Oct; 67(4):e150-1. PubMed ID: 22980274
[No Abstract] [Full Text] [Related]
16. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Ryan C; Kirby B; Collins P; Rogers S
Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
[TBL] [Abstract][Full Text] [Related]
17. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
18. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
Nakayama C; Fujita Y; Watanabe M; Shimizu H
J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
